All In Biotech

Drug Trial Radar · NCT04419623

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Last checked: Nov 19, 2026Latest source record: May 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Jul 9, 2020

Primary completion

Sep 22, 2020

Study completion Dec 15, 2020

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jun 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was enrolled and the study did not proceed into Phase 2.

Conditions

  • COVID-19
  • Sars-CoV2
  • Cancer
  • Solid Tumor
  • Carcinoma
  • Blood Cancer

Interventions

  • TL-895Drug

    TL-895, administered by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended dose of TL-895Time frame: After the day 14 of the 6th subject per dose level

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Georgia Cancer Center

    Augusta, Georgia

  • The Ohio State Comprehensive Cancer Center

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.